Latuda (lurasidone) carries two FDA black box warnings, its most serious safety alerts: increased death risk in elderly patients with dementia-related psychosis, and increased suicidal thoughts in young adults. Beyond those, the drug can cause a rare but life-threatening reaction called neuroleptic malignant syndrome, potentially permanent involuntary movements, and hormonal disruptions. Here’s what each of these risks actually looks like and who’s most vulnerable.
Black Box Warnings: The Highest-Level Risks
The FDA reserves black box warnings for the most dangerous effects of a medication. Latuda has two.
The first applies to elderly patients with dementia-related psychosis. Across 17 placebo-controlled trials of atypical antipsychotics, the death rate in drug-treated patients was about 4.5% over 10 weeks, compared to 2.6% on placebo. That’s roughly 1.6 to 1.7 times the risk. Most deaths were cardiovascular (heart failure, sudden death) or infectious (pneumonia). Latuda is not approved for treating dementia-related psychosis, but the warning exists because antipsychotics are sometimes prescribed off-label in this population.
The second warning covers suicidal thoughts and behavior in people under 25. In pooled data from roughly 77,000 adult patients and over 4,400 pediatric patients, antidepressant-class drugs increased suicidal thinking in younger age groups. For adults aged 18 to 24, the data showed about 5 additional cases of suicidal thoughts or behaviors per 1,000 patients treated, compared to placebo. No completed suicides occurred in the pediatric studies. This warning applies because Latuda is prescribed for bipolar depression, placing it alongside other medications that affect mood pathways.
Neuroleptic Malignant Syndrome
Neuroleptic malignant syndrome (NMS) is rare but can be fatal. It’s a medical emergency triggered by drugs that affect dopamine signaling in the brain, including Latuda. The hallmarks are high fever, severe muscle rigidity, confusion or altered consciousness, and wild swings in blood pressure. Excessive sweating and rapid heart rate are also common. Muscle rigidity can become severe enough to cause muscle tissue breakdown, which can damage the kidneys. If you or someone you know develops a high fever with stiff muscles and confusion while taking Latuda, this needs emergency medical attention immediately.
Tardive Dyskinesia: Potentially Permanent Movement Problems
Tardive dyskinesia involves involuntary, repetitive movements, most often of the face, tongue, and jaw. Lip smacking, tongue thrusting, and grimacing are typical. The critical concern is that these movements can become permanent, even after stopping the medication.
In clinical trials measuring shifts from normal to abnormal involuntary movements, 7.4% of adults with schizophrenia on Latuda showed new abnormal movements, compared to 5.8% on placebo. For adults with bipolar depression using Latuda alone, the rate was 3.4% versus 1.2% on placebo. The risk generally increases with longer use and higher doses, and older adults are more susceptible.
Akathisia: Intense Inner Restlessness
Akathisia is one of the most distressing side effects people report on Latuda, and it’s more common than the rare reactions listed above. It creates an overwhelming, uncontrollable urge to move. People describe it as an intense internal restlessness, nervousness, mounting tension, and an inability to sit still or relax. It’s not just fidgeting. The sensation can cause extreme anxiety and distress, and for some people it’s severe enough to make the medication intolerable. Standing in line, sitting through a meeting, or trying to fall asleep can feel unbearable.
Hormonal Disruption and Reproductive Effects
Latuda blocks dopamine receptors, which can raise levels of the hormone prolactin. Elevated prolactin can interfere with reproductive function in both men and women. In women, this can mean missed periods, irregular cycles, or unexpected breast milk production. In men, it can cause breast tissue enlargement or erectile dysfunction.
In clinical trials, 3.6% of Latuda-treated patients had prolactin levels elevated to five times the upper limit of normal, compared to 0.7% on placebo. Women were hit harder: 8.3% of women on Latuda had significant elevations, versus 1% on placebo. For men, the rates were 1.9% versus 0.6%. The effect is dose-dependent, meaning higher doses carry more risk.
Blood Pressure Drops and Fainting
Latuda can cause orthostatic hypotension, a sudden drop in blood pressure when you stand up. This can lead to dizziness, lightheadedness, a racing or slowed heartbeat, and in some cases fainting. The risk is highest when first starting the medication, restarting after a break, or increasing the dose. In clinical trials the overall incidence was low (0.4% for orthostatic hypotension, under 0.1% for fainting), but the consequences of a fall, particularly for older adults, can be serious.
White Blood Cell Count Changes
Latuda can cause drops in white blood cell counts, a condition that weakens the immune system and increases vulnerability to infections. People with already low white blood cell counts or a history of this problem need frequent blood monitoring during the first few months of treatment. If counts drop severely (below 1,000 neutrophils per cubic millimeter), the medication should be stopped. Warning signs include unexplained fever, sore throat, or other signs of infection.
Metabolic Effects Are Relatively Mild
Compared to other atypical antipsychotics, Latuda has a relatively favorable metabolic profile, which is worth noting since metabolic problems are a major concern with this drug class. In pooled six-week trials, the average weight gain on Latuda was 0.9 kg (about 2 pounds), and one 12-month study actually showed a slight weight loss of 1 kg. Blood sugar changes were essentially zero: the median change in fasting glucose was 0.0 mg/dL in both short-term and long-term studies. By comparison, drugs like olanzapine and quetiapine showed significantly more weight gain and metabolic disruption in the same analyses. This doesn’t mean Latuda is risk-free metabolically, but it’s notably better than several alternatives.
Why Taking It With Food Matters
Latuda must be taken with at least 350 calories to be absorbed properly. When taken on an empty stomach, your body absorbs roughly half the intended dose. In pharmacokinetic studies, the peak blood concentration nearly tripled when the drug was taken with a 350-calorie meal compared to fasting, and the total drug exposure approximately doubled. This means taking it without food doesn’t just make it less effective. It creates inconsistent drug levels, which can worsen side effects on days you do eat with it and reduce effectiveness on days you don’t. The fat content of the meal doesn’t matter much; calorie count is what drives absorption.